Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer : a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022
© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology..
BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer.
METHODS: We extracted studies on non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) using the PubMed, Ichushi Web, and Cochrane Library databases. Two reviewers assessed the extracted studies for each type of lung cancer and conducted quantitative and meta-analyses of preplanned outcomes, including overall survival, FN incidence, infection-related mortality, quality of life, and musculoskeletal pain.
RESULTS: A limited number of studies were extracted: two on NSCLC and six on SCLC. A meta-analysis was not conducted owing to insufficient data on NSCLC. Two case-control studies explored the efficacy of primary prophylaxis with G-CSF in patients with NSCLC (on docetaxel and ramucirumab therapy) and indicated a lower FN frequency with G-CSF. For SCLC, meta-analysis of five studies showed no significant reduction in FN incidence, with an odds ratio of 0.38 (95% confidence interval 0.03-5.56, P = 0.48). Outcomes other than FN incidence could not be evaluated due to low data availability.
CONCLUSION: Limited data are available on G-CSF prophylaxis in lung cancer. Primary prophylaxis with G-CSF may be weakly recommended in Japanese patients with NSCLC undergoing docetaxel and ramucirumab combination therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
International journal of clinical oncology - 29(2024), 4 vom: 01. März, Seite 355-362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ichihara, Eiki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
143011-72-7 |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10147-024-02469-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36844015X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36844015X | ||
| 003 | DE-627 | ||
| 005 | 20240326235417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10147-024-02469-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM36844015X | ||
| 035 | |a (NLM)38353907 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ichihara, Eiki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer |b a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. | ||
| 520 | |a BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer | ||
| 520 | |a METHODS: We extracted studies on non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) using the PubMed, Ichushi Web, and Cochrane Library databases. Two reviewers assessed the extracted studies for each type of lung cancer and conducted quantitative and meta-analyses of preplanned outcomes, including overall survival, FN incidence, infection-related mortality, quality of life, and musculoskeletal pain | ||
| 520 | |a RESULTS: A limited number of studies were extracted: two on NSCLC and six on SCLC. A meta-analysis was not conducted owing to insufficient data on NSCLC. Two case-control studies explored the efficacy of primary prophylaxis with G-CSF in patients with NSCLC (on docetaxel and ramucirumab therapy) and indicated a lower FN frequency with G-CSF. For SCLC, meta-analysis of five studies showed no significant reduction in FN incidence, with an odds ratio of 0.38 (95% confidence interval 0.03-5.56, P = 0.48). Outcomes other than FN incidence could not be evaluated due to low data availability | ||
| 520 | |a CONCLUSION: Limited data are available on G-CSF prophylaxis in lung cancer. Primary prophylaxis with G-CSF may be weakly recommended in Japanese patients with NSCLC undergoing docetaxel and ramucirumab combination therapy | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a G-CSF | |
| 650 | 4 | |a Non-small-cell lung cancer | |
| 650 | 4 | |a Small-cell lung cancer | |
| 650 | 7 | |a Granulocyte Colony-Stimulating Factor |2 NLM | |
| 650 | 7 | |a 143011-72-7 |2 NLM | |
| 650 | 7 | |a Docetaxel |2 NLM | |
| 650 | 7 | |a 15H5577CQD |2 NLM | |
| 650 | 7 | |a Ramucirumab |2 NLM | |
| 650 | 7 | |a D99YVK4L0X |2 NLM | |
| 700 | 1 | |a Ochi, Nobuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Makimoto, Go |e verfasserin |4 aut | |
| 700 | 1 | |a Kudo, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Daijiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ozaki, Yukinori |e verfasserin |4 aut | |
| 700 | 1 | |a Nishio, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuchihashi, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Endo, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Yano, Shingo |e verfasserin |4 aut | |
| 700 | 1 | |a Maruyama, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshinami, Tetsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Susumu, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Takekuma, Munetaka |e verfasserin |4 aut | |
| 700 | 1 | |a Motohashi, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Mamoru |e verfasserin |4 aut | |
| 700 | 1 | |a Baba, Eishi |e verfasserin |4 aut | |
| 700 | 1 | |a Uchino, Keita |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kamiyama, Yutaro |e verfasserin |4 aut | |
| 700 | 1 | |a Nakao, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Tamura, Shinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimoto, Hitomi |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Yasuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Toshimi |e verfasserin |4 aut | |
| 700 | 1 | |a Kubo, Toshio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical oncology |d 1997 |g 29(2024), 4 vom: 01. März, Seite 355-362 |w (DE-627)NLM095566163 |x 1437-7772 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:4 |g day:01 |g month:03 |g pages:355-362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10147-024-02469-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 4 |b 01 |c 03 |h 355-362 | ||